Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL

US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news